- Conditions
- Bradycardia
- Interventions
- Micra AV Transcatheter Pacing System
- Device
- Lead sponsor
- Medtronic
- Industry
- Eligibility
- Not listed
- Enrollment
- 802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Rancho Mirage, California • Redwood City, California + 37 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 5,349
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Heart Failure
- Interventions
- HeartWare® VAS, Control LVAD
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 39 more
- Conditions
- Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Major Salivary Gland Cancer AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Verrucous Carcinoma AJCC v7, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Verrucous Carcinoma AJCC v7, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Verrucous Carcinoma AJCC v7, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Major Salivary Gland Cancer AJCC v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7, Tongue Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Cisplatin, Docetaxel, Fluorouracil, Laboratory Biomarker Analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2027
- U.S. locations
- 777
- States / cities
- Mobile, Alabama • Fairbanks, Alaska • Fort Smith, Arkansas + 472 more
- Conditions
- Higher Risk Myelodysplastic Syndromes
- Interventions
- bexmarilimab (1mg/kg), azacitidine, Placebo, bexmarilimab (3mg/kg)
- Drug
- Lead sponsor
- Faron Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 9
- States / cities
- Duarte, California • Aurora, Colorado • New Haven, Connecticut + 6 more
- Conditions
- Prostate Cancer
- Interventions
- Investigators choice of SoC, AAA817
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 35
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Related Hematopoietic Stem Cell Donors
- Interventions
- Not listed
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Not listed
- Enrollment
- 1,812 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • San Diego, California • San Francisco, California + 44 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Cytarabine or Supportive Care, Dacogen (decitabine) only
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 37
- States / cities
- Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 34 more
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
- Interventions
- CB-010, Cyclophosphamide, Fludarabine
- Genetic · Drug
- Lead sponsor
- Caribou Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 27 more
- Conditions
- Liposarcoma, Dedifferentiated
- Interventions
- Brigimadlin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 21 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 3 Months and older
- Enrollment
- 3,515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 39 more
- Conditions
- Head and Neck Cancer
- Interventions
- filgrastim, cisplatin, paclitaxel, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2013
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
- Conditions
- Pre-term Infants
- Interventions
- study pre-term formula
- Other
- Lead sponsor
- Abbott Nutrition
- Industry
- Eligibility
- Up to 21 Days
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Mobile, Alabama • South Bend, Indiana • Wichita, Kansas + 4 more
- Conditions
- Esophagitis, Reflux, Esophagitis, Peptic
- Interventions
- Dexlansoprazole MR, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 96
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more
- Conditions
- Type 2 Diabetes
- Interventions
- INCB013739, Placebo comparator matching INCB013739, Metformin
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Artesia, California • Calabasas, California + 54 more
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Ibandronate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Female only
- Enrollment
- 1,711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 128 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- AST-120, Celphere® CP-305
- Drug
- Lead sponsor
- Ocera Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 13
- States / cities
- Huntsville, Alabama • Sacramento, California • San Diego, California + 10 more
- Conditions
- Congenital Heart Disease
- Interventions
- Not listed
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Up to 12 Weeks
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin • Milwaukee, Wisconsin
- Conditions
- Schizophrenia
- Interventions
- placebo, Ziprasidone oral capsules
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • San Diego, California • Stanford, California + 34 more
- Conditions
- Myocardial Infarction, Anemia
- Interventions
- Red Blood Cell Transfusion
- Biological
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 60
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Danbury, Connecticut + 48 more
- Conditions
- HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Capecitabine, Cixutumumab, Lapatinib Ditosylate, Quality-of-Life Assessment
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 390
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 274 more
- Conditions
- Cervical Cancer
- Interventions
- carboplatin, cisplatin, paclitaxel, intensity-modulated radiation therapy, standard external beam radiation therapy, Optional brachytherapy boost
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 119
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 98 more
- Conditions
- Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pain questionnaires
- Behavioral
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 279
- States / cities
- Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 181 more
- Conditions
- Lung Cancer Screening
- Interventions
- Lung Cancer Screening Decision Tool, Control Intervention
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 3
- States / cities
- West Haven, Connecticut • Philadelphia, Pennsylvania • Milwaukee, Wisconsin